Broker note9 May 2022 12:09
Must say looks good. I just put off by spread/liquidity in this market…..
“ FY 2021 results 4basebio’s full-year results to 31 December 2021 reflect consistent progress towards its main objectives, with recently completed clean rooms undergoing validation ahead of targeted DNA production towards the year end. It generated revenues of £0.34m with a pre-tax loss of £3.64m (FY 2020: £0.72m) and ended the period with £9.6m cash, providing it with a cash runway into 2023 and an undrawn loan facility of €25m. When fully operational, this facility will be able to produce DNA with a value in excess of £25m pa and c.80% gross margins. In the meantime, the company continues to build partnerships, with four disclosable agreements signed to date and many that remain under NDAs. We have made changes to forecasts to reflect increased investment in R&D and headcount and reiterate our sum-of-the-parts DCF target price of 1,200p. This is underpinned by the expected high demand for DNA and the significant potential of its technology to address key challenges in the cell and gene therapy space. ”
Usual caveats
Trek